Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
151
resultados
Última actualización
14/07/2026 [07:49:00]
Resultados 75 a 100 de 151
Resumen de: WO2026128809A1
Provided are compositions including a cell or cells that reduce or attenuate hybrid insulin peptide (HIP) formation, for example, a cell or cells that include an insulin gene with a genetic modification in the C-peptide sequence of the insulin gene. Also provided are methods of using the cell or cell to treat autoimmune disorders, such as type 1 diabetes (T1D), and methods of treating autoimmune disorders, such as type 1 diabetes (T1D), including inhibiting or attenuating cathepsin D (CatD) activity, and identifying CatD inhibitors to treat autoimmune disorders, such as type 1 diabetes (T1D).
Resumen de: WO2026123353A1
The present invention belongs to the technical field of medical devices and particularly relates to a dual closed-loop insulin delivery system, use thereof, and a medical product thereof. Disclosed is a dual closed-loop insulin delivery system, specifically comprising a continuous glucose monitoring system, a dual closed-loop control algorithm, an insulin pump, and a specific glucose-responsive insulin analog. The present invention controls blood glucose in a dual closed-loop mode and can achieve a high time-in-range and more stable, safer, and simpler blood glucose control. Moreover, no human intervention is required during the use of the system. The present invention provides a more intelligent and user-friendlier treatment scheme for diabetic patients.
Resumen de: US20260166094A1
0000 The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.
Resumen de: US20260165661A1
0000 A device for generating alerts for Hypo and Hyperglycemia Prevention from Continuous Glucose Monitoring (CGM) determines a dynamic risk based on both information of glucose level and a trend obtainable from a CGM signals. The device includes a display whose color depends on the DR (for example, red for high DR, green for low risk). When DR exceeds a certain threshold, alerts are generated to suggest the patient to pay attention to the current glucose reading and to its trend, both of which are shown on the display in numbers and symbols (e.g. an arrow with different slope or color).
Resumen de: WO2026124490A1
A blood glucose data monitoring method for a blood glucose monitoring device, and a system, relating to the technical field of continuous glucose monitoring. The method comprises: determining motion state parameters of a user on the basis of test parameters respectively corresponding to an acceleration sensor and an angular velocity sensor at the current moment, wherein the motion state parameters comprise an acceleration vector force and an angular velocity change value; determining a tilt angle value of a blood glucose monitoring device on the basis of the motion state parameters; and determining the current motion state of the user on the basis of the tilt angle value, and matching a corresponding blood glucose monitoring algorithm on the basis of the current motion state, so as to determine the current blood glucose data of the user. The technical solution can achieve accurate identification of motion states of users, so as to achieve adjustment of related blood glucose monitoring algorithms on the basis of the motion states, thereby improving the accuracy of blood glucose value monitoring for the users.
Resumen de: US20260166227A1
0000 The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include adjusting user specific dosage parameters in response to one or more back-filled time segments associated with a diurnal time block.
Resumen de: US20260166219A1
0000 A user-wearable patch pump system for delivery of insulin or other medicament can include a pump and an attachment portion that attaches the pump to a user's body. The pump can include a drive unit and a disposable cartridge containing a medicament with the drive unit configured to cause the pump to deliver the medicament in the cartridge to the user. The attachment portion can include a retention frame configured to selectively retain the pump therein and an adhesive patch configured to be attached to the user's body. The pump can be selectively attached to the retention frame and used to deliver medicament either through a cannula to an infusion site directly beneath the retention frame or through tubing to an infusion site displaced from the retention frame.
Resumen de: US20260165622A1
0000 This disclosure relates to a glucose-sensing electrode including a nanoporous metal layer and an electrolyte ion-blocking layer formed over the nanoporous metal layer. The nanoporous metal layer is capable of oxidizing both glucose and maltose without an enzyme specific to glucose in the glucose-sensing electrode. The electrolyte ion-blocking layer is configured to inhibit Na<+>, K<+>, Ca<2+>, Cl<−>, PO<4>3− and CO<3>2− from diffusing toward the nanoporous metal layer such that there is a substantial discontinuity of a combined concentration of Na<+>, K<+>, Ca<2+>, Cl<−>, PO<4>3− and CO<3>2− between over and below the electrolyte ion-blocking layer.
Resumen de: WO2025137203A1
The present invention relates generally to systems, devices, and methods for in vivo monitoring of an analyte level. In particular, the present invention relates to sensors having saccharides or similar molecules present in glucose-oxidase containing sensing layers to improve sensor stability.
Resumen de: US20260166225A1
0000 Systems, computer programs, devices, and methods that enable coordination across multiple devices of the mobile ecosystem. In one embodiment, smart glasses detect when a user is about to eat food or take a drink and capture the consumable and portion. The data is recorded in a “morsel track” for health activity analysis. Low-fidelity captures provide preliminary recognition, while higher-fidelity captures are selectively invoked for definitive classification. Machine-learning logic generates predicted metabolic responses, such as real-time glucose trends, based on the recorded events. Predicted responses may dynamically adjust the operation of continuous glucose monitors, heart-rate sensors, or other biomedical devices. In some embodiments, the system triggers a pharmaceutical dispenser, such as an insulin pump, inhaler, or transdermal patch, to provide closed-loop therapeutic intervention in real time.
Resumen de: US20260171205A1
Technologies are provided for insulin delivery. According to some aspects, a system may receive therapy-related data and settings associated with a first insulin infusion device used to deliver insulin to a user during a time period. The system may detect events during the period, via an event detection system, wherein each detected event comprises a specific activity that is indicative of a physical behavior of the user. The system may process the therapy-related data and settings to identify one or more physiological periods of the user, occurring during the time period, based on the detected events and the therapy-related data and settings, and may determine a physiological blood response of the user during the identified one or more physiological periods of the user. The system may output insulin delivery information for delivering insulin to the user based at least in part on the determined physiological blood response.
Resumen de: WO2025034851A1
Exemplary embodiments may configure the glucose cost component of a cost function used in determining basal insulin delivery doses to be limited by the maximum physiological rate of glucose level change over a time period so that the cost function more accurately reflects the physical limits of change due to insulin action, As a result, the glucose cost component of the cost function may more accurately reflect the response of a user to basal insulin deliveries, resulting in better insulin control for the user. Exemplary embodiments may modify the aggressiveness of a control approach based on a current target glucose level versus a nominal target glucose level for which the control approach was designed.
Resumen de: GB2702575A
A skin contact sensor 100 for detecting a biomarker in the interstitial fluid of a user such as a subject’s glucose or hydration levels. The sensor comprises a reusable electronics part and a disposable medical patch. The medical patch comprises a substrate 40 with a plurality of electrodes 60, conductive elements 70 (like tracks) and a contact interface 80. The substrate 40 may have a support member (90, figure 4c) and the contact interface 80 may be non-integral to the substrate 40. The reusable electronics are electrically connected to the medical patch via the contact interface 80 by an electrical connector (30, figure 4c) and removably secured to the medical patch by an adhesive such as double-sided tape. Electrical contact between the electrodes 60 and patient’s skin is provided by a conductive gel which also serves as a medium into which interstitial fluid is extracted during use and can also contain enzymes to aid in target detection. Figure 1a.
Resumen de: EP4759223A1
This invention relates to medical devices, particularly a continuous glucose monitoring (CGM) device designed for the diagnosis and monitoring of metabolic diseases such as diabetes. The invention offers an innovative monitoring solution for both type 1 diabetes, which arises from insufficient insulin production, and the more common type 2 diabetes, which is associated with insulin resistance. By enabling continuous blood sugar monitoring, the invention provides a user-friendly, eco-friendly, and cost-effective solution for diabetes management. The device allows real-time monitoring of glucose levels and delivers visual, auditory, and vibrational alerts to the user. As a result, it establishes a safer, more practical, and continuous health management system for users.
Resumen de: US20260157664A1
The blood glucose measuring device includes a processor and a memory storing instructions, wherein the instructions, when executed by the processor, cause the blood glucose measuring device to obtain, via a first receiver, a plurality of reflection signals, which is a plurality of lights output from the light source, and obtain, via a second receiver, a plurality of transmission signals, determine, for each of the plurality of reflection signals and each of the plurality of transmission signals, a slope efficiency, which represents a ratio of an output change to an input change of the blood glucose measuring device, determine first analysis data based on the slope efficiency of the plurality of reflection signals and/or second analysis data based on the slope efficiency of the plurality of transmission signals, and determine a final blood glucose value based on at least one of the first analysis data or the second analysis data.
Resumen de: US20260159864A1
0000 A standardized plant extract is produced by cultivating undifferentiated or differentiated in vitro cultures of Haberlea rhodopensis Friv. (HR), followed by harvesting the biomass and extracting bioactive compounds and primary and secondary metabolites, including organic acids, fatty acids, amino acids, sterols, free phenols, sugars, and polyphenols. The extraction process is performed under controlled conditions to yield an extract with a predominant myconoside content of 70% to 96% in the polyphenolic fraction, constituting 18% to 35% of the total extract. The extract may be combined with glycerol to form a composition with standardized myconoside content. The resulting extract or biomass is then incorporated into products for the pharmaceutical, cosmetic, or food industries. This method provides a consistent, renewable, and sustainable source of raw material, eliminating dependence on wild plant populations and seasonality, and delivers valuable health-protective properties.
Resumen de: WO2026120569A1
A system includes a wearable device and a charger case. The wearable device is configured to be positioned on an ear of a wearer, and includes first and second body portions and a connection member mechanically coupled to each of the first body portion and the second body portion. The first body portion and/or the second body portion includes a processor, a memory, and a sensor set including at least one of a pulse oximeter, a photoplethysmogram (PPG) sensor, an accelerometer, a temperature sensor, a proximity sensor, an ambient light sensor, or a gyroscopic sensor. The memory stores instructions to cause the processor to calculate at least one of a blood oxygen saturation level, a pulse rate, a blood pressure level, a blood flow rate, a cardiac output/rhythm, a blood sugar level, a blood carbon monoxide level, a blood nitrous oxide level, or an electrocardiogram of the wearer.
Resumen de: US20260157662A1
The device for dynamic determination of a slow insulin dose to be injected comprises: a means (21) of acquiring multiple blood glucose levels during a first day and the day following the first day,a means (26) of calculating the difference in blood glucose levels,a means (22, 24, 25, 42, 43) of determining if a predetermined event has occurred between going to bed and getting up,a means (26) of determining, if no predetermined event has occurred, a hyperglycaemia or a hypoglycaemia depending on the difference in blood glucose levels,a means (26) of determining if at least a predetermined number of hyperglycaemias or hypoglycaemias have occurred in a predetermined period of time,a means (26) of modifying the slow insulin to be injected, in this case of an occurrence, anda means (25) of indicating a numerical value of the modified slow insulin dose to be injected.
Resumen de: WO2026119202A1
Provided are a variant of glucagon-like peptide-1 (GLP-1) and use thereof. It has been discovered that GLP-1 can be degraded by an insulin-degrading enzyme (IDE), and degradation sites thereof are identified. Moreover, a GLP-1 variant with enhanced stability is designed, and the cellular secretion level and stability of GLP-1 are improved by regulating the IDE.
Resumen de: WO2026119866A1
The present invention relates to a computer-implemented method for predicting a risk for a subject to experience an analyte concentration in a bodily fluid above a predetermined glucose event threshold at the end of a predetermined predicting time interval, a data processing system, a computer program, a system, and remote control. The disclosure, thus, relates to the management of diabetes. The risk is predicted based on a plurality of input parameters and using a machine learning model.
Resumen de: US20260158171A1
The disclosure provides insulin-glucagon-like peptide 1 (GLP-1) polynucleotides for delivery to pancreatic islet cells, as well as compositions comprising the polynucleotides and methods of treating obesity-associated metabolic disorders.
Resumen de: US20260158217A1
A diabetes management system including a wearable device having an elongated support patch with an adhesive disposed on a skin side, a sensor portion disposed on a non-skin side and including an electrochemical glucose sensor and a wireless communication module, and a medication delivery portion disposed on a non-skin side and comprising a medication reservoir and a medication pump. The system also includes a behavior tracking device having a tracking wireless communication module, a portable electronic device configured to communicate wirelessly to the wearable device and the behavior tracking device, and a controller. The sensor portion is configured to detect a glucose level of a subject and the controller is configured to receive the glucose level and to transmit to the medication pump an instruction which causes the medication pump to deliver a dose to the subject of a medication based on the glucose level.
Resumen de: WO2026120503A1
The technology provides a system and method for assessing loss of vibration perception in a subject. It may be useful for the self-diagnosis, self-monitoring and self-treatment of adverse health conditions such as cutaneous neuropathy or diabetic foot, and for developing related prognoses. The system comprises a wearable or handheld vibration device which includes piezoelectric elements. These may be actuated to produce vibrations which are transmitted to the body surface of the subject by a probe. A communications apparatus is provided so that data can be transferred between the vibration device and a computing device such as a smartphone. The computing device is arranged to control levels of intensity of vibration of the piezoelectric elements, to record data representing levels of intensity of vibration, and to record and track input data entered by the user, corresponding to levels of intensity of vibration at which the subject perceives the transmitted vibrations via their body surface.
Resumen de: US20260157702A1
0000 Control device (30) for determining an amount of carbohydrate (RC) recommendation. The control device comprises a retrieving unit (32), the retrieving unit (32) being configured to retrieve user data, an outlier unit (34), the outlier unit (34) being configured to determine whether a user data is considered to be an outlier or not, an RC unit (36), the RC unit (36) being configured to estimate an RC recommendation using mathematical functions of the user data; and a transmission unit (38), the transmission unit (38) being configured to transmit the RC recommendation. The transmission unit (38) is configured to transmit the RC recommendation if and only if the last user data is not considered to be an outlier.
Nº publicación: EP4756833A1 10/06/2026
Solicitante:
MEDTRUM TECH INC [CN]
Medtrum Technologies Inc.
Resumen de: EP4756833A1
The invention discloses a diabetes management system for use in a hospital, including: at least a wearable medical device, a plurality of receivers, a central server and a healthcare provider terminal, the receivers receive the data information transmitted by the medical device and upload it to the central server, and the healthcare provider communicates with the central server and displays or reviews the medical data information through the terminal, as any one of the multiple receivers can receive the data information transmitted by the medical device and upload it to the central server, as a result, the patient's range of motion in the hospital is no longer restricted, which improves the patient's experience and keeps the patient in a comfortable mood, while the healthcare provider is able to know the patient's blood glucose level and/or insulin infusion state in real time through the healthcare provider terminal and deal with the abnormalities in a timely manner, so that the patient's blood glucose level can be maintained at a stable level.
BOPI
Sede Electrónica
